adrenergic agonists potentiate chemosensitivity whilst another study did not. 7 The ventilatory Background -It has previously been shown that fenoterol, a 2 adrenergic agon-response to hypercapnia or hypoxia in patients with chronic obstructive pulmonary disease ist, increases the ventilatory response to hypoxia (HVR) and hypercapnia (HCVR) (COPD) continues to be debated. Patients with carbon dioxide retention were found to have a in normal subjects. The effects of 2 adrenergic agonists on chemoreceptors in decreased response to carbon dioxide while non-hypercapnic patients had a normal patients with chronic obstructive pulmonary disease (COPD) remain con-response.
used was similar to that of Whitelaw and co-max and Pmax were repeated until three measurements varying by <5% and sustained for workers. 16 Volume was obtained from electrical integration of the flow signal which was meas-one second or longer were recorded. The highest value thus obtained was reported. ured at the mouthpiece. The P 0.1 was obtained from a mouth pressure measured 100 ms after Placebo or fenoterol (15 mg) was administered as three divided doses in a double the onset of inspiration, as defined by the appearance of a negative mouth pressure. The blind crossover design for a week and then changed to the alternative for a week with no expiratory side was sampled continuously using a mass spectrometer (WSMR-1400; Westron, washout period. The ventilatory response tests (HCVR and HVR) and the pulmonary function Chiba, Japan). The subjects breathed air until they became accustomed to the circuit by by-tests were examined at the same time on the seventh day of each treatment. Subjects were passing the rebreathing bag to room air. They then rebreathed a gas mixture of 7% carbon asked to refrain from other drugs such as other adrenergic agonists, theophylline, sedatives, dioxide and 93% oxygen from a six litre rebreathing bag. During rebreathing the in-caffeine-containing beverages, and alcohol for 24 hours before the test day. On each test day spiratory side of the circuit was occluded randomly every 4-6 breaths. Rebreathing was the tests were performed two hours after taking the placebo or fenoterol. The baseline measusually terminated within 3-4 minutes. The V  was obtained as the average for the two urements of the lung function tests, respiratory muscle strength, heart rate, and blood pressure breaths that preceded the breath from which the P 0.1 was measured. Simultaneously, the end were measured at rest and then the ventilatory responses to hypercapnia and hypoxia were tidal partial pressure of carbon dioxide (P 2 ) was measured. The ventilatory re-assessed. The order of the ventilatory tests was randomised with at least 10 minutes rest sponse to hypercapnia was assessed from the slope of the linear regression between V  and between each test.
All values are expressed as mean (SD) unless P 2 , and between P 0.1 and P 2 ( V / P 2 and P 0.1 / P 2 , respectively). otherwise specified. Statistical analysis was performed using the Wilcoxon signed rank test. The ventilatory response to hypoxia was measured by the progressive isocapnic hypoxia A p value of less than 0.05 was considered significant. A prestudy power calculation inmethod of Rebuck. 17 The subjects used the same rebreathing circuit as for the ventilatory dicated that, with 21 subjects, this study had an 80% chance of detecting a true change in response to hypercapnia, except that a rebreathing bag containing eight litres of gas HCVR or HVR of more than 19%, which was calculated from data in our previous study. 6 mixture (3.5% carbon dioxide, 23% oxygen, and 73.5% nitrogen) and a bypass carbon di-The STATISTICA statistical software package (StatSoft, Tulsa, USA) was used. oxide absorber were used. During the test the arterial oxygen saturation (Sa 2 ) was monitored with a pulse oximeter (Biox IIA, Biox Technology, Boulder, USA). During re-Results
The patients had severe airway obstruction with breathing the P 2 was kept constant at the resting level of each subject during room air a mean FEV 1 /VC of 50 (14)% and increased lung volumes as shown in table 1. Hypoxaemia breathing by removing carbon dioxide from the circuit with a variable AC motor fan connected (Pa 2 <10 kPa) was observed in six of 20 patients and hypercapnia (Pa 2 >6 kPa) in to a bypass carbon dioxide absorber. Rebreathing was continued until Sa 2 decreased only one. Fenoterol treatment for one week increased the mean FEV 1 from 1.66 (0.70) l to 75-80%. The ventilatory response to hypoxia was calculated from the slope of the linear to 1.79 (0.89) l (p<0.05) with no significant change in sGaw or FRC. The mean Pmax at regression of plots of V  versus Sa 2 and P 0.1 versus Sa 2 ( V / Sa 2 and P 0.1 / Sa 2 , re-FRC was 52 (21)% of our normal value (see Appendix) and was increased by a mean of spectively).
Respiratory muscle strength was assessed by 16% following fenoterol treatment (p<0.02), whereas the Pmax was 58 (21)% of normal measuring mouth pressures during maximal static inspiratory (Pmax) and expiratory (P-and did not change following fenoterol. The heart rate was increased by 7% from 74.5 (10.5) max) efforts against a closed valve with a small air leak to prevent glottic closure.
18 Pmax was to 79.8 (9.1) beats/min (p<0.01) following fenoterol but there was no significant change in measured at FRC and residual volume, and Pmax at FRC and total lung capacity with a Pa 2 , Pa 2 , or blood pressure.
The minute ventilation showed a trend to differential pressure transducer (Validyne MP-45±250 mm Hg). The determinations of P-increase with fenoterol from a mean (SD) of group.bmj.com on April 7, 2017 -Published by http://thorax.bmj.com/ Downloaded from 12.9 (2.8) l/min with placebo to 14.2 (3.4) l/ min after fenoterol (p=0.06), although neither the V, breathing frequency, nor P 2 showed any significant change. The P 0.1 during air breathing did not differ between the two treatments at 0.20 (0.09) versus 0.23 (0.09) kPa, whereas the V/T of 0.57 (0.12) l/min on fenoterol was significantly higher than the 0.52 (0.12) l/min when on placebo (p<0.02).
Our patients showed a wide range of ventilatory responses to hypercapnia (HCVR) and hypoxia (HVR). Fenoterol increased the slope of P 0.1 versus P 2 ( P 0.1 / P 2 ) by 23%, from a mean (SD) of 0.35 (0.23) kPa/kPa with placebo to 0.43 (0.24) kPa/kPa (p<0.01; fig 1) . The slope of V  versus P 2 ( V / P 2 ) showed a trend to increase with fenoterol from a mean (SD) of 9.2 (3.4) with placebo to 10.5 (13.8) on placebo to 34.9 (15.0) l/min on fenoterol (p<0.01). The slopes of the response curves to hypoxia ( P 0.1 / Sa 2 and V / Sa 2 ) were greater than for the normal subjects in our previous study 6 (both p<0.02). Fenoterol did not change the slope of either V  or P 0.1 versus Sa 2 , as shown in fig 3, but from fig 1  it can be seen that the P 0.1 at an Sa 2 value of 80% was significantly increased from a mean of 0.90 (0.72) to 0.97 (0.55) kPa following fenoterol treatment (p<0.05) whereas V  was unchanged at 80% oxygen saturation.
Discussion
We have shown that fenoterol significantly increased the ventilatory response to hypercapnia in patients with COPD but caused a nonsignificant trend to increase their response to patients with COPD, fenoterol may stimulate the central chemoreceptor with a lesser effect on the peripheral chemoreceptor.
To be certain that these findings are true it is necessary to consider whether our experimental method or protocol could have influenced the result. Ventilatory responses were measured two hours after the last oral dose of fenoterol because plasma levels reach a maximum at this time 20 and, with a half life of only 6-7 hours, there was no need for a prolonged washout period. We therefore believe that the results truly reflect the effects of the drug and placebo. Blood levels were not checked but we had no reason to suspect that our subjects were not complying with the dose regimen.
The rebreathing techniques 15 17 used for HCVR and HVR were first designed for normal subjects based on the assumption that a relation between V  and P 2 or between V  and Sa 2 is linear. One concern when using the V  lationship was not affected by fenoterol and so Those patients who were hypoxaemic were we believe that the rebreathing techniques of found by some authors to have a reduced ventilRead and Rebuck were valid tests for our subatory response to hypoxia, 11 12 whereas others jects. Because of the concern that V  may be have found these patients to have an increased affected by the presence of airflow limitation, HVR. 13 The HVR in our patients was greater we also used P 0.1 as a measure of respiratory than that of the normal subjects in our previous output. P 0.1 may be influenced by changes in study 6 ( V /Sa 2 −0.22 (0.06) for normal submuscle strength or lung volume 21 and in our jects versus −0.87 (0.49) l/min/% for patients subjects fenoterol increased Pmax by 16% but with COPD, p<0.01). In our study only the did not alter FRC. However, we found that most hypoxaemic patient (Pa 2 =6.3 kPa) had P 0.1 when breathing air was not changed by a decreased HVR; Pa 2 in the remaining fenoterol and so we believe that this change in patients was more than 8.3 kPa. In our previous muscle strength was not affecting P 0.1 in our study in normal subjects we found a reduced tests. We also found that fenoterol increased response to hypoxia compared with the results FEV 1 but had no effect on sGaw, and others from some studies 11 26 but our finding was simhave found that bronchodilation with atropine ilar to that of others, 13 and it is accepted that did not affect P 0.1 whereas resistive unloading there is a wide range of HVR responses in with helium/oxygen reduced it. 22 It therefore normal subjects. In those studies in which a seems that fenoterol is unlikely to influence P 0.1 reduced HVR response was found in patients by its effects on airway mechanics. For a given with COPD 11 12 most of the patients were hyp-P 0.1 the mean inspiratory flow will increase if oxaemic and so the different finding in our flow resistance decreases, and we found that the study may be due to the fact that our patients V/T whilst breathing air increased following were essentially normoxic. fenoterol while the P 0.1 did not change. It has Fenoterol increased the slopes of both P 0.1 been reported in patients with COPD that the and V  during the HCVR, but that of V  did effective inspiratory impedance decreased after not reach significance. The position of the P 0.1 fenoterol only in those patients who had an and V  response curves at P 2 of 8 kPa was increase in their FEV 1 . 23 We found no difference moved to a higher value by fenoterol treatment. in the effective impedance between our placebo The increase in the P 0.1 response by fenoterol and fenoterol groups, and so the recorded in-was similar to that found in normal subjects 6 crease in FEV 1 after fenoterol in our subjects and the smaller change in V  compared with may have been too small to change the effective P 0.1 may be due to the effect of airflow limimpedance.
Figure 3 Hypoxic ventilatory response (HVR
itation. The effect of fenoterol on HVR is weak Patients with COPD are characterised by and so its action on the peripheral chemoincreased neuromuscular inspiratory drive and receptors seems limited. The increased reincreased effective inspiratory impedance. 24 In sponse to carbon dioxide with fenoterol could our patients with COPD the P 0.1 and V/T be due to an action on central chemoreceptors were comparable with that found in our normal but this putative action remains controversial. subjects. 6 The effective inspiratory impedance, Some, but not all, studies have shown that P 0.1 /(V/T), during air breathing did not differ 2 adrenergic agonists potentiate ventilatory from that of the normal subjects (0.40 (0.14) chemosensitivity 5-7 and those studies underversus 0.38 (0.22) kPa/l/min) and this similarity taken on humans, 5 6 together with the current suggests that our patients had no increased study, have shown that 2 adrenergic agonists neuromuscular drive and that their airflow lim-stimulate HCVR which suggests an effect on itation was not sufficiently severe to increase the central chemoreceptor. the effective inspiratory impedance.
The position of the P 0.1 response curve at The abnormalities of control of breathing 80% Sa 2 in the HVR was augmented by fenin patients with COPD remain controversial. oterol treatment, although the slope of the Hypercapnic patients have a diminished response curve was not changed. The effect of HCVR, while the HCVR in non-hypercapnic fenoterol on the HVR may be weak in patients patients is normal.
8 9 It has also been reported with COPD. In our previous study fenoterol that the HCVR in patients with COPD is lower increased both the slope and the position of than in normal subjects, although there is no P 0.1 at 80% Sa 2 of HVR in normal subjects. 6 difference in the HCVR between hypercapnic The Pa 2 did not differ between placebo and and non-hypercapnic patients. 10 On the con-fenoterol, suggesting that the level of carbon trary, patients with COPD are reported to have dioxide may not affect the HVR. Little is known a normal or increased response to hypercapnia about the effects of 2 adrenergic agonists on the when measured with diaphragmatic electro-ventilatory response to hypoxia. Isoprenaline myography, although the P 0.1 response slope stimulates the carotid body through a adis decreased. 25 In the present study hypercapnia renergic mechanism 3 4 and fenoterol has weak was observed in only one patient but the in-1 activity in spite of being a relatively selective crease in Pa 2 was slight (6.4 kPa). His P 0.1 / 2 adrenergic agonist. 27 It is therefore possible P 2 was normal but he had a low V / that fenoterol increases the response of the P 2 . The average values of P 0.1 / P 2 carotid body to hypoxia through 1 activity.
The plasma potassium level is a putative poand V / P 2 in our patients were com- 
